Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Free AccessOriginal communication

Bailout stenting in femoropopliteal arterial segment

Published Online:December 14, 2021https://doi.org/10.1024/0301-1526/a000986

Abstract

Summary:Background: Disabling peripheral arterial disease (PAD) of femoropopliteal segment is usually treated with percutaneous balloon dilatation, and when this is not successful, stent is placed. Long-term patency of stent is often compromised due to in-stent restenosis (ISR). We aimed to identify factors associated with bailout stenting, and to recognise risk factors for ISR in procedures without paclitaxel application. Patients and methods: We analysed 592 consecutive successful femoropopliteal interventions performed in patients with either disabling intermittent claudication or chronic critical limb ischemia (CLI). In patients with stent implantation, clinical and ultrasound (US) examination were performed one year after the intervention to establish the presence of ISR, defined as >50% stenosis on US imaging. Results: Bailout stenting was required in 133 (22.5%) procedures. Patients with stent placement were younger (70±10 vs 72±11 years, p=0.007) and less often presented with CLI (29.3% vs 40.5%, p=0.019). They more often reported smoking (63.2% vs 49.2%, p=0.005), less often had diabetes mellitus (35.3% vs 47.5%, p=0.013) and arterial hypertension (82.0% vs 90.8%; p=0.004). Stenting was also dependent on lesion complexity (TASC II C>B>A; p<0.001). Subgroup analysis of 110 procedures with bare metal stent (BMS) placement performed in 107 patients revealed ISR in 46.4% of stents, in half of cases it was symptomatic. Neither clinical nor lesion characteristics proved to differ between the group of procedures with ISR and group of procedures without ISR. Conclusions: Factors associated with bailout stenting were age, diabetes mellitus, arterial hypertension, smoking, clinical picture of PAD and complexity of treated lesions. We did not find any risk factors influencing development of ISR in BMS.

References

  • 1 Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. ESVM guideline on peripheral arterial disease. VASA. 2019;48:1–79. First citation in articleLink, Google Scholar

  • 2 Kasapis C, Henke PK, Chetcuti SJ, Koenig GC, Rectenwald JE, Krishnamurthy VN, et al. Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2008;30:44–55. First citation in articleCrossref Medline, Google Scholar

  • 3 Chowdhury MM, McLain AD, Twine CP. Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev. 2014;2014(6):CD006767. First citation in articleGoogle Scholar

  • 4 Ho KJ, Owens CD. Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis. J Vasc Surg. 2017;65:545–57. First citation in articleCrossref Medline, Google Scholar

  • 5 Razzouk L, Aggarwal S, Gorgani F, Babaev A. In-stent restenosis in the superficial femoral artery. Ann Vasc Surg. 2013;27:510–24. First citation in articleCrossref Medline, Google Scholar

  • 6 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24). First citation in articleCrossref Medline, Google Scholar

  • 7 Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–63. First citation in articleCrossref Medline, Google Scholar

  • 8 Nordanstig J, James S, Andersson M, Andersson M, Danielsson P, Gillgren P, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med. 2020;383:2538–46. First citation in articleCrossref Medline, Google Scholar

  • 9 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5–67. First citation in articleCrossref Medline, Google Scholar

  • 10 Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J. 2017;2018(39):763–816. First citation in articleGoogle Scholar

  • 11 Schillinger M, Minar E. Endovascular stent implantation for treatment of peripheral artery disease. Eur J Clin Invest. 2007;37:165–70. First citation in articleCrossref Medline, Google Scholar

  • 12 Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte K-L, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length. Circulation. 2007;116:285–92. First citation in articleCrossref Medline, Google Scholar

  • 13 Shanmugasundaram M, Murugapandian S, Truong HT, Lotun K, Banerjee S. Drug-coated balloon in peripheral artery disease. Cardiovasc Revascularization Med. 2019;20:338–43. First citation in articleCrossref Medline, Google Scholar

  • 14 Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery. Circ Cardiovasc Interv. 2010;3:267–76. First citation in articleCrossref Medline, Google Scholar

  • 15 Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–9. First citation in articleCrossref Medline, Google Scholar

  • 16 Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease. Circ Cardiovasc Interv. 2011;4:495–504. First citation in articleCrossref Medline, Google Scholar

  • 17 Fujihara M, Takahara M, Sasaki S, Nanto K, Utsunomiya M, Iida O, et al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease. J Endovasc Ther. 2017;24:367–75. First citation in articleCrossref Medline, Google Scholar

  • 18 Nguyen BN, Conrad MF, Guest JM, Hackney L, Patel VI, Kwolek CJ, et al. Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent. J Vasc Surg. 2011;54:1051–7. First citation in articleCrossref Medline, Google Scholar

  • 19 Kamioka N, Soga Y, Kuramitsu S, Iida O, Hirano K, Suzuki K, et al. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the retrospective multicenter analysis for femoropopliteal stenting (REAL-FP). Catheter Cardiovasc Interv. 2017;90:790–7. First citation in articleCrossref Medline, Google Scholar

  • 20 Stavroulakis K, Torsello G, Manal A, Schwindt A, Hericks C, Stachmann A, et al. Results of primary stent therapy for femoropopliteal peripheral arterial disease at 7 years. J Vasc Surg. 2016;64:1696–702. First citation in articleCrossref Medline, Google Scholar

  • 21 Gao M, Zhao X, Tao Y, Wang L, Xia M, Tong Z, et al. Incidence and predictors of in-stent re-stenosis in the superficial femoral artery: evaluation of long-term outcomes by color duplex ultrasound. Ultrasound Med Biol. 2016;42:717–26. First citation in articleCrossref Medline, Google Scholar

  • 22 Steiner S, Schmidt A, Bausback Y, Piorkowski M, Werner M, Yahiaoui-Doktor M, et al. Midterm patency after femoropopliteal interventions. J Endovasc Ther. 2016;23:347–55. First citation in articleCrossref Medline, Google Scholar

  • 23 Qato K, Conway AM, Mondry L, Giangola G, Carroccio A. Management of isolated femoropopliteal in-stent restenosis. J Vasc Surg. 2018;68:807–10. First citation in articleCrossref Medline, Google Scholar

  • 24 Bausback Y, Wittig T, Schmidt A, Zeller T, Bosiers M, Peeters P, et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease. J Am Coll Cardiol. 2019;73:667–79. First citation in articleCrossref Medline, Google Scholar

  • 25 Ihnat DM, Duong ST, Taylor ZC, Leon LR, Mills JL, Goshima KR, et al. Contemporary outcomes after superficial femoral artery angioplasty and stenting: The influence of TASC classification and runoff score. J Vasc Surg. 2008;47:967–74. First citation in articleCrossref Medline, Google Scholar